Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camonsertib + PARP inhibitors in advanced solid tumors
NCT04972110Phase 2Terminated
- Sponsor
- Repare Therapeutics
- Start
- Jul 2021
- Primary completion
- Nov 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of camonsertib in solid tumor (advanced stage) (2 arms), sponsored by Repare Therapeutics. Primary endpoints: Safety and Tolerability of Niraparib or Olaparib in Combination With RP-3500 up to 23.7 months and Recommended Phase 2 Dose at 21 days. Started Jul 2021; status: terminated.
02
Drugs
camonsertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04972110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04972110.